Literature DB >> 30955513

Chronic Obstructive Pulmonary Disease: Evaluation and Management.

Sean P Duffy1, Gerard J Criner2.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of death nationally and worldwide. Cigarette smoking is the most common risk factor in the development of COPD. Disease course is variable with some patients having a high degree of obstruction and minimal symptoms, whereas others with better lung function have a greater symptoms burden. The goal of pharmacologic therapy is to minimize symptoms, improve exercise tolerance, and reduce exacerbation risk. No pharmacologic therapy has been shown to improve survival in COPD. Pulmonology referral is recommended for patients with COPD with symptoms despite first-line inhaled therapy, frequent exacerbations, any hospitalizations, or moderate-to-severe disease.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute exacerbation; COPD; Chronic bronchitis; Emphysema

Mesh:

Year:  2019        PMID: 30955513     DOI: 10.1016/j.mcna.2018.12.005

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  33 in total

1.  Nursing Outcomes and Risk Factors of Patients with Chronic Obstructive Pulmonary Disease After Discharge.

Authors:  Yun-Hua Chai; Hui Yang; Gai-Ping Huang; Ting Wu; Yan Dong
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-10-21

2.  The Relationship between Serum Uric Acid Levels and Early Mortality in Chronic Obstructive Pulmonary Disease Cases during Exacerbation.

Authors:  Gökhan Büyükbayram; Ömer Yüceer; Fatma Sema Oymak
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-06-29       Impact factor: 1.803

3.  Respiration-related guidance and nursing can improve the respiratory function and living ability of elderly patients with chronic obstructive pulmonary disease.

Authors:  Xiaoyan Sun; Yu Shen; Jian Shen
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

4.  Effectiveness and safety of acupoint application for chronic obstructive pulmonary disease: A protocol for updated systematic review and meta-analysis.

Authors:  Hao-Yang Zhang; Han Huang; Li-Jian Pang; Xiao-Dong Lv; Wei-Dong Zheng
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

5.  lncRNA TUG1 regulates human pulmonary microvascular endothelial cell apoptosis via sponging of the miR-9a-5p/BCL2L11 axis in chronic obstructive pulmonary disease.

Authors:  Xichen Chen; Mao Mao; Ying Shen; Xueyong Jiang; Zhifei Yin
Journal:  Exp Ther Med       Date:  2021-06-25       Impact factor: 2.447

6.  Correlation between serum IL-32 concentration and clinical parameters of stable COPD: a retrospective clinical analysis.

Authors:  Biaoxue Rong; Tian Fu; Congxue Rong; Wen Liu; Kai Li; Hua Liu
Journal:  Sci Rep       Date:  2020-07-21       Impact factor: 4.379

7.  Exploration of n-6 and n-3 Polyunsaturated Fatty Acids Metabolites Associated with Nutritional Levels in Patients with Severe Stable Chronic Obstructive Pulmonary Disease.

Authors:  Mingshan Xue; Chuanxu Cai; Lili Guan; Yifan Xu; Jinsheng Lin; Yifeng Zeng; Haisheng Hu; Rongchang Chen; Hongman Wang; Luqian Zhou; Baoqing Sun
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-07-10

8.  COPD from an everyday primary care point of view.

Authors:  Antonio L Aguilar-Shea; Julio Bonis
Journal:  J Family Med Prim Care       Date:  2019-08-28

9.  Extracellular adenosine triphosphate is associated with airflow limitation severity and symptoms burden in patients with chronic obstructive pulmonary disease.

Authors:  Iva Hlapčić; Andrea Hulina-Tomašković; Anita Somborac-Bačura; Marija Grdić Rajković; Andrea Vukić Dugac; Sanja Popović-Grle; Lada Rumora
Journal:  Sci Rep       Date:  2019-10-25       Impact factor: 4.379

10.  Effects of Jianpi Yiqi method for chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis.

Authors:  Yuxi Wang; Yihui Jiang; Junchen Ge; Zhiwei Zhang; Jia Dong
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.